National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 54700 [2021-21530]
Download as PDF
<![CDATA[
54700
Federal Register / Vol. 86, No. 189 / Monday, October 4, 2021 / Notices
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report, SF–429 Real
Property Status Report (Cover Page),
SF–429–A Real Property Status Report
ATTACHMENT A (General Reporting),
SF–429–B Real Property Status Report
ATTACHMENT B (Request to Acquire,
Improve or Furnish), and SF–429–C
Real Property Status Report
ATTACHMENT C (Disposition or
Encumbrance Request) forms allow the
applicants to provide real property
details as part of their grant proposals.
These forms are evaluated by Federal
agencies as part of the overall grant
application. This IC expires on February
28, 2022. Grants.gov seeks a three-year
clearance of these collections.
Type of Respondent: The
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report, SF–429 Real
Property Status Report (Cover Page),
SF–429–A Real Property Status Report
ATTACHMENT A (General Reporting),
SF–429–B Real Property Status Report
ATTACHMENT B (Request to Acquire,
Improve or Furnish), and SF–429–C
Real Property Status Report
ATTACHMENT C (Disposition or
Encumbrance Request) forms are used
by organizations to apply for Federal
financial assistance in the form of
grants. These forms are submitted to the
Federal grant-making agencies for
evaluation and review.
ANNUALIZED BURDEN HOUR TABLE
Forms
(if necessary)
Respondents
(if necessary)
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report.
SF–429 Real Property Status Report (Cover
Page), SF–429–A Real Property Status
Report.
ATTACHMENT A (General Reporting), SF–
429–B Real Property Status Report.
ATTACHMENT B (Request to Acquire, Improve or Furnish), and SF–429–C Real
Property.
Status Report ATTACHMENT C (Disposition or Encumbrance Request).
Total .......................................................
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2021–21558 Filed 10–1–21; 8:45 am]
BILLING CODE 4151–AE–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Number of
respondents
22:52 Oct 01, 2021
Jkt 256001
Average
burden per
response
Total burden
hours
Grant-seeking organizations
100,000
1
0.5
50,000
Grant-seeking organizations
100,000
1
1
100,000
Grant-seeking organizations
100,000
1
1
100,000
Grant-seeking organizations
100,000
1
100,000
........................
Grant-seeking organizations
100,000
1
1
........................
........................
1
........................
450,000
...............................................
Early Life (IDEaL) (U01, U19 Clinical Trial
Not Allowed).
Date: October 26–27, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Margaret A. Morris Fears,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, (301) 761–5444,
maggie.morrisfears@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21530 Filed 10–1–21; 8:45 am]
BILLING CODE 4140–01–P
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Immune Development in
VerDate Sep<11>2014
Number of
responses per
respondents
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Initial Review Group;
Medication Development Research Study
Section.
Date: November 3, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 86, Number 189 (Monday, October 4, 2021)]
[Notices]
[Page 54700]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21530]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Immune Development in Early Life
(IDEaL) (U01, U19 Clinical Trial Not Allowed).
Date: October 26-27, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Margaret A. Morris Fears, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, (301) 761-5444, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-21530 Filed 10-1-21; 8:45 am]
BILLING CODE 4140-01-P
